Key result
CIEDs in S. aureus bacteremia are linked to ~11% higher 30-day mortality versus matched controls.
Why the study?
Complete CIED removal is advised after Staphylococcus aureus bacteremia, but clinical outcomes in CIED carriers required nationwide estimation.
Does CIED removal reduce mortality and reinfection in patients with Staphylococcus aureus bacteremia compared to retained devices?
Cohort (n=10,896)
Yes
Does CIED removal reduce mortality and reinfection in patients with Staphylococcus aureus bacteremia compared to retained devices?
In patients with CIEDs and S. aureus bacteremia, device removal is associated with significantly lower mortality and reinfection rates, yet it is performed in only a small, selected proportion of younger and healthier patients.
Answers are grounded in this paper and cite their sources.
Highlights excess short-term mortality risk in CIED patients with S. aureus bacteremia; leaves open whether device removal improves outcomes.
BACKGROUND: In case of Staphylococcus aureus bacteremia (SAB), complete cardiac implantable electronic device (CIED) removal is advised by the European Heart Rhythm Association. OBJECTIVES: The objective of the study was to estimate clinical outcomes after SAB in the Danish CIED carriers. METHODS: We conducted a nationwide register-based cohort study including all patients with SAB after CIED implantation between 2000 and 2020. Cumulative incidence of device removal, SAB reinfection, and all-cause mortality were estimated and compared to sex and age-matched non-CIED controls with SAB. Landmark analysis at the time of hospital discharge estimating mortality and reinfection according to CIED removal status in surviving patients was conducted. RESULTS: In total, 1,816 patients with CIED and SAB and 9,080 matched controls were included in the study (median age 77.5 years, 73.0% males). Thirty-day all-cause mortality was 34.0% (95% CI: 31.8%-36.2%) in patients with CIED and 31.0% (95% CI: 30.0%-31.9%) in controls (P = 0.019, adjusted HR: 1.11 [95% CI: 1.02-1.22]). Device removal within 30 days was performed in 286 patients (15.8%). The landmark analysis showed significantly lower 180-days cumulative incidence of SAB reinfection and all-cause mortality in patients undergoing device removal compared to those with retained CIEDs (reinfection: 2.5% vs 5.5%; mortality: 7.8% vs 31.2%). Patients who underwent CIED removal were younger and had less comorbidity compared to those with retained CIEDs. CONCLUSIONS: The Danish CIED carriers had slightly higher 30-day all-cause mortality after SAB compared to matched controls. Only a minor selected proportion underwent device removal after SAB diagnosis and, after initial survival, these patients had lower 180-days reinfection rates and mortality compared to patients with retained devices.
No takes yet. Share an insight, caveat, or question.
Bengtsen et al. (2026) conducted a cohort in Staphylococcus aureus bacteremia in patients with cardiac implantable electronic devices (n=10,896). Cardiac implantable electronic device (CIED) vs. Matched non-CIED controls was evaluated on 30-day all-cause mortality (adjusted HR 1.11, 95% CI 1.02-1.22, p=0.019). Cardiac implantable electronic device carriers with Staphylococcus aureus bacteremia had higher 30-day all-cause mortality than matched controls (34.0% vs 31.0%; adjusted HR 1.11, 95% CI 1.02-1.22).
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: